Fellowship · Miami, FL
Sponsored by University of Miami/Jackson Health System
Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways.
Cancer discovery · 2023 · 146 citations · Doured Daghistani
Base Editing of HBG1 and HBG2 Promoters for Sickle Cell Disease.
The New England journal of medicine · 2026 · 16 citations · Edward Ziga
Characterization of COVID-19 disease in pediatric oncology patients: The New York-New Jersey regional experience.
Pediatric blood & cancer · 2021 · 90 citations · Bradley Gampel
Anemia and Associated Risk Factors in Pediatric Patients.
Pediatric health, medicine and therapeutics · 2023 · 22 citations · Fernando Corrales-Medina
Phase I dose escalation and expansion trial of single agent ONC201 in pediatric diffuse midline gliomas following radiotherapy.
Neuro-oncology advances · 2022 · 53 citations · Doured Daghistani
Consensus definition of essential, optimal, and suggested components of a pediatric sickle cell disease center.
Pediatric blood & cancer · 2023 · 19 citations · Ofelia Alvarez
Three-year results from phase I of ZUMA-4: KTE-X19 in pediatric relapsed/refractory acute lymphoblastic leukemia.
Haematologica · 2023 · 38 citations · Edward Ziga
Safety and pharmacokinetics of ONC201 (dordaviprone) administered two consecutive days per week in pediatric patients with H3 K27M-mutant glioma.
Neuro-oncology · 2024 · 22 citations · Doured Daghistani